Sandoz Specialty Summit 2024: Advancing patient access to quality treatments

According to Charaf Eddine Kadri, general director of Sandoz Vietnam, the company is committed to supporting healthcare professionals.

With the growing cancer burden in Vietnam, Sandoz is committed to supporting healthcare professionals with innovative oncology therapies like Rituximab biosimilar to improve patient outcomes.

Similarly, treatments like acid zoledronic represent a significant step forward in managing osteoporosis.

“By addressing not just treatment effectiveness but also patient compliance, we can make a profound impact on public health. Events like this summit are a vital platform to share insights and drive innovation together with healthcare professionals,” he said.

With Vietnam facing a significant cancer burden, where over 180,000 new cases and 120,000 cancer-related deaths were reported in 2022, the summit placed a special emphasis on oncology.

Non-communicable diseases, including cancers such as lung, liver, and breast cancer, account for 77 per cent of the country’s total deaths.

“This makes the need for effective and affordable cancer treatments even more pressing,” he said.

The summit highlighted Rituximab biosimilar for treating non-Hodgkin lymphoma. Picture: Sandoz Vietnam

The summit highlighted Rituximab biosimilar for treating non-Hodgkin lymphoma, showcasing real-world data and insights from major international conferences like the American Society of Hematology 2024 and the European Hematology Association (EHA) 2024.

In addition, Rituximab biosimilar has been shown to be effective via many clinical studies, providing many RA-ILD patients with access to biological therapies.

Gefitinib Sandoz, a promising therapy for non-small cell lung cancer, was also featured, reflecting the need for accessible treatments that can improve outcomes in Vietnam’s second-most prevalent and challenging cancer to treat.

The summit also spotlighted acid zoledronic for osteoporosis management, emphasising patient compliance to reduce fractures and enhance quality of life for ageing populations.

In addition to oncology, the summit focused on osteoporosis. With Vietnam emerging as one of the most rapidly ageing countries in the world, osteoporosis is becoming an increasingly important issue.

Many patients, particularly the elderly, are at risk of fractures, which significantly impact their quality of life. The summit’s discussions emphasised how improving patient compliance with accessible treatments such as acid zoledronic can help reduce fractures and re-fractures while offering cost-effective solutions to manage osteoporosis.

According to Dr. Sreedhar Sagi, medical director of International Region at Sandoz, biosimilars offer patients more treatment options, delivering significant benefits for public health by improving access to advanced therapies.

"With Sandoz leading the global research and development of biosimilars, including our robust portfolio of 11 approved products and 25 more in development, we are at the forefront of addressing unmet medical needs. Events like this summit underscore our commitment to partnering with healthcare professionals to drive innovation and improve lives. Access to innovation has one key rule: ‘The only treatment that works is one that we can afford to give,” Sagi said.

The summit provided a comprehensive platform for knowledge exchange, with sessions focusing on multiple therapeutic areas, including insurance budget management, osteoporosis, rheumatoid arthritis, haematology, and oncology. It offered an opportunity for healthcare professionals to engage with leading experts, exchange best practices, and explore how innovative therapies can be integrated into patient care in Vietnam.

Sandoz enters a new era as independent firm Sandoz, a global leader in generic and biosimilar medicines, successfully completed its separation from Novartis on October 4 with its first trading day on the SIX Swiss Exchange (SIX).

Sandoz and Vietnam National Cancer Hospital sign MoU to improve standards of care for oncology patients Sandoz, the global leader in generic and biosimilar medicines, and the Vietnam National Cancer Hospital signed a partnership on June 12 to improve the standards of care offered to oncology patients in Hanoi and around the nation.

Sandoz launches scheme to combat antimicrobial resistance Sandoz, a global player in generic and biosimilar medicines, announced the launch of its inaugural community programme on Antimicrobial Resistance (AMR) at a press conference in Hanoi on November 22